Related Experiment Videos
Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor
Rajeev Dhupar1, Lauren Van Der Kraak1, Arjun Pennathur1
1Department of Cardiothoracic Surgery, Division of Thoracic and Foregut Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Abstract:
Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern immunotherapies. An emergent notion relates success with checkpoint inhibitors with high mutational load tumors. There are few studies that examine checkpoint protein expression and relate these to clinical outcomes after the conventional treatment of patients with esophageal cancer, which has a high mutational load. The objective of this review is to summarize the literature that examines checkpoint expression and clinical outcomes, as well as propose an accelerated approach to introducing these therapies into the clinic to treat patients with esophageal cancer.
Insights
Checkpoint inhibitors, such as PD-1 and CTLA-4 antibodies, are revolutionizing cancer immunotherapy. This review examines their expression in esophageal cancer and proposes faster clinical integration for this high-mutation-load cancer.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Checkpoint inhibitors (programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) represent a significant advancement in cancer therapy.
- Esophageal cancer is characterized by a high mutational load, suggesting potential sensitivity to immunotherapies.
- Limited research exists on checkpoint protein expression and its correlation with clinical outcomes in esophageal cancer following conventional treatment.
Purpose of the Study:
- To review existing literature on checkpoint protein expression in esophageal cancer.
- To correlate checkpoint expression with clinical outcomes in patients treated with conventional therapies.
- To propose strategies for accelerating the clinical implementation of checkpoint inhibitor therapies for esophageal cancer.
Main Methods:
- Comprehensive literature search of studies examining checkpoint protein expression (PD-1, PD-L1, CTLA-4) in esophageal cancer.
- Analysis of clinical outcomes in relation to checkpoint protein expression.
- Review of current treatment paradigms and emerging immunotherapy approaches.
Main Results:
- Emerging evidence suggests a link between high tumor mutational load and response to checkpoint inhibitors.
- Data on specific checkpoint protein expression and its direct impact on esophageal cancer patient outcomes post-conventional therapy is scarce.
- The review synthesizes current knowledge gaps and identifies areas for future research.
Conclusions:
- Checkpoint inhibitors hold promise for esophageal cancer treatment, particularly given its high mutational burden.
- Further research is needed to elucidate the role of specific checkpoint proteins in esophageal cancer.
- An accelerated clinical introduction of these immunotherapies is warranted, supported by further investigation.